Skip to main content

13 Result(s)

within Robert L Martuza Remove this filter English Remove this filter Oncology Remove this filter

and

  1. No Access

    Article

    A Monoclonal Antibody Against β1 Integrin Inhibits Proliferation and Increases Survival in an Orthotopic Model of High-Grade Meningioma

    High-grade meningiomas (HGMs; World Health Organization [WHO] classification grade II and III) have high relapse rates and poor clinical outcomes despite surgery and radiation treatments. No effective medical ...

    Fares Nigim, Juri Kiyokawa, Alessandra Gurtner, Yoichiro Kawamura… in Targeted Oncology (2019)

  2. No Access

    Article

    Single agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma

    Anti-angiogenic therapy is a promising therapeutic strategy for the highly vascular and malignant brain tumor, glioblastoma (GBM), although current clinical trials have failed to demonstrate an extension in ov...

    Lei Lu, Dipongkor Saha, Robert L. Martuza, Samuel D. Rabkin… in Journal of Neuro-Oncology (2015)

  3. Article

    Open Access

    Identification of diagnostic serum protein profiles of glioblastoma patients

    Diagnosis of a glioblastoma (GBM) is triggered by the onset of symptoms and is based on cerebral imaging and histological examination. Serum-based biomarkers may support detection of GBM. Here, we explored ser...

    Anja Elstner, Florian Stockhammer, Trong-Nghia Nguyen-Dobinsky… in Journal of Neuro-Oncology (2011)

    Download PDF (437 KB) View Article

  4. No Access

    Article

    The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma

    Purpose Temozolomide (TMZ), given concurrently with radiotherapy (RT) and as adjuvant monotherapy afterwards, has led to improved survival in glioblastoma multiforme (GBM). However, it is unclear whether its prim...

    David J. Sher, John W. Henson, Bindu Avutu, Fred H. Hochberg… in Journal of Neuro-Oncology (2008)

  5. No Access

    Article

    Oncolytic viral therapies – the clinical experience

    It has been 9 years since the beginning of the first clinical trial in which an oncolytic virus was administered to cancer patients. Since then, oncolytic viruses from five different species have been taken to...

    Manish Aghi, Robert L Martuza in Oncogene (2005)

  6. No Access

    Article

    Differential modulation of malignant peripheral nerve sheath tumor growth by omega-3 and omega-6 fatty acids

    Neurofibromatosis type 1 (NF1) is a common genetic disorder of the nervous system resulting in neurofibromas and malignant peripheral nerve sheath tumors (MPNST). In this study, we report the modulation of mur...

    George A Mashour, Stephanie N Drissel, Silke Frahm, Faris Farassati… in Oncogene (2005)

  7. No Access

    Article

    The angiogenic factor midkine is aberrantly expressed in NF1-deficient Schwann cells and is a mitogen for neurofibroma-derived cells

    Loss of the tumor suppressor gene NF1 in neurofibromatosis type 1 (NF1) contributes to the development of a variety of tumors, including malignant peripheral nerve sheath tumors (MPNST) and benign neurofibromas. ...

    George A Mashour, Nancy Ratner, Galam A Khan, Huey-Ling Wang, Robert L Martuza… in Oncogene (2001)

  8. No Access

    Article

    Craniofacial Hemangiopericytoma Associated with Oncogenic Osteomalacia: Case Report

    A craniofacial hemangiopericytoma associated with oncogenic osteomalacia is described and the literature is reviewed. A 46 year-old male with multiple fractures and hypophosphatemia was found to have a craniof...

    Faheem A. Sandhu, Robert L. Martuza in Journal of Neuro-Oncology (2000)

  9. No Access

    Article

    Frequent loss of chromosome 14 in atypical and malignant meningioma: identification of a putative `tumor progression' locus

    Formation of meningiomas has been associated with the loss of genetic material on chromosome 22. To approach the additional chromosomal events that underlie progression of these tumors to malignancy, we have e...

    Anil G Menon, Joni L Rutter, Jean Paul von Sattel, Heidi Synder… in Oncogene (1997)

  10. No Access

    Article

    Inhibition of angiogenesis and growth of human non-malignant and malignant meningiomas by TNP-470

    Meningiomas are relatively common (22%) vascular brain tumors. 3–11% of meningiomas are malignant, and defy currently available therapy. Inhibition of neovascularization is one potential strategy for treating ...

    Takahito Yazaki, Yoshiaki Takamiya, Penelope C. Costello… in Journal of Neuro-Oncology (1995)

  11. No Access

    Article

    Growth of human acoustic neuromas, neurofibromas and schwannomas in the subrenal capsule and sciatic nerve of the nude mouse

    To develop a reproducible in vivo model for the growth of human acoustic neuromas and neurofibromas, we implanted tumor specimens (6 acoustic neuromas; 4 neurofibromas; 3 schwannomas arising in skin and soft tiss...

    Jung Kyo Lee, Raymond A. Sobel, E. Antonio Chiocca, Tai S. Kim… in Journal of Neuro-Oncology (1992)

  12. No Access

    Chapter

    Genetic Alterations of Nervous System Tumors

    The last decade has witnessed revolutionary advances in our understanding of the basic molecular changes associated with carcinogenesis in general and with nervous system tumorigenesis in particular. This repo...

    Robert L. Martuza in Biological Aspects of Brain Tumors (1991)

  13. No Access

    Article

    Photodynamic therapy is potentiated by Co60 and intratumoral injection of hematoporphyrin derivative

    Hematoporphyrin derivative injected directly into a subcutaneous rat glioma resulted in a significant greater tumor growth inhibition than hematoporphyrin derivative injected parenterally upon stimulation by l...

    Herwig Kostron, Mitchel R. Swartz, Robert L. Martuza in Journal of Neuro-Oncology (1988)